ChainCatcher report, according to GLOBE NEWSWIRE, NewGenIVF Group (Nasdaq: NIVF) has signed an agreement to acquire an additional 3% equity stake in K25.ai at a $250 million valuation, increasing its ownership from 10% to 13%. The consideration for this transaction is approximately $7.5 million, with NewGen planning to issue about 2.5 million shares of Class A common stock as partial payment. Post-issuance, the company’s total outstanding shares will rise to approximately 5.9 million, potentially elevating its market capitalization above $5 million, aiding its compliance with Nasdaq’s listing requirements. Based on the latest valuation, NewGen’s previous $10 million investment in K25.ai now corresponds to a book value of approximately $25 million. K25.ai is an AI-native platform for live streaming and information markets, which has recently completed its community testing and is accelerating expansion across the Asia-Pacific region.
NewGenIVF Increases Its Stake in K25.ai to 13% at a $250 Million Valuation
ChaincatcherShare
Summary
NewGenIVF (NASDAQ: NIVF) has increased its stake in K25.ai to 13% at a $250 million valuation, acquiring an additional 3% through a $7.5 million transaction. The deal involves issuing 2.5 million Class A shares, bringing the total number of shares to 5.9 million. K25.ai, an AI-native live-streaming platform, is expanding into the Asia-Pacific region following community testing. Altcoins to watch may include K25.ai as transaction volume rises with its market entry.
Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.